Jun 4 2009
Scientists and engineers at UC Santa Barbara and other researchers have developed a nanoparticle that can attack plaque - a major cause of cardiovascular disease. The new development is described in a recent issue of the Proceedings of the National Academy of Sciences.
This is an image of a multifunctional micelle designed by research team. Credit: Peter Allen, UCSB College of Engineering
The treatment is promising for the eventual development of therapies for cardiovascular disease, which is blamed for one third of the deaths in the United States each year. Atherosclerosis, which was the focus of this study, is one of the leading causes of cardiovascular disease. In atherosclerosis, plaque builds up on the walls of arteries and can cause heart attack and stroke.
"The purpose of our grant is to develop targeted nanoparticles that specifically detect atherosclerotic plaques," said Erkki Ruoslahti, distinguished professor at the Burnham Institute for Medical Research at the University of California, Santa Barbara. "We now have at least one peptide, described in the paper, that is capable of directing nanoparticles to the plaques."
The nanoparticles in this study are lipid-based collections of molecules that form a sphere called a micelle. The micelle has a peptide, a piece of protein, on its surface, and that peptide binds to the surface of the plaque.
Co-author Matthew Tirrell, The Richard A. Auhll Professor and dean of UCSB's College of Engineering, specializes in lipid-based micelles. "This turned out to be a perfect fit with our targeting technology," said Ruoslahti.
To accomplish the research, the team induced atherosclerotic plaques in mice by keeping them on a high-fat diet. They then intravenously injected these mice with the micelles, which were allowed to circulate for three hours.
"One important element in what we did was to see if we could target not just plaques, but the plaques that are most vulnerable to rupture," said Ruoslahti. "It did seem that we were indeed preferentially targeting those places in the plaques that are prone to rupture."
The plaques tend to rupture at the "shoulder," where the plaque tissue meets the normal tissue. "That's also a place where the capsule on the plaque is the thinnest," said Ruoslahti. "So by those criteria, we seem to be targeting the right places."
Tirrell added:"We think that self-assembled micelles (of peptide amphiphiles) of the sort we have used in this work are the most versatile, flexible nanoparticles for delivering diagnostic and therapeutic biofunctionality in vivo. The ease with which small particles, with sufficiently long circulation times and carrying peptides that target and treat pathological tissue, can be constructed by self-assembly is an important advantage."
Ruoslahti said that UCSB's strength in the areas of materials, chemistry, and bioengineering facilitated this research. He noted that he and Tirrell have been close collaborators.
The work was funded by a grant from the National Heart, Lung and Blood Institute of the National Institutes of Health.
In addition to Ruoslahti and Tirrell, the article, "Targeting Atherosclerosis Using Modular, Multifunctional Micelles," was authored by David Peters of the Burnham Institute at UCSB and the Biomedical Sciences Graduate Group at UC San Diego; Mark Kastantin of UCSB's Department of Chemical Engineering; Venkata Ramana Kotamraju of the Burnham Institute at UCSB; Priya P. Karmali of the Cancer Research Center, Burnham Institute for Medical Research in La Jolla; and Kunal Gujraty of the Burnham Institute at UCSB.